Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080795 | 0.84 | FOLH1 (0.30) | — | |
| SCHEMBL25500051 | 0.84 | MMP1 (0.39) | KMT2AMMP1MMP3 | |
| SCHEMBL23080559 | 0.82 | MMP1 (0.39) | KMT2AMMP1MMP3 | |
| SCHEMBL23080567 | 0.82 | MMP1 (0.39) | MMP1MMP2MMP3 | |
| SCHEMBL25495899 | 0.79 | CAPN1 (0.33) | KMT2AMMP1ALDH1A1CAPN1MEN1 | |
| SCHEMBL25501433 | 0.79 | PSMB5 (0.33) | HTRA1ALDH1A1LMNA | |
| SCHEMBL25968542 | 0.78 | ALDH1A1 (0.32) | KMT2AALDH1A1POLBLMNACHRM5 | |
| SCHEMBL31635869 | 0.75 | ALDH1A1 (0.42) | KMT2AHTRA1ALDH1A1LMNACHRM5 | |
| SCHEMBL25500045 | 0.73 | MMP1 (0.40) | MMP1MMP2MMP3 | |
| SCHEMBL25444781 | 0.73 | MMP1 (0.42) | KMT2AMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 2571/4885HTRA1 1060/4885MMP1 2356/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | KMT2A 2571/4885HTRA1 1060/4885MMP1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.